A new treatment option for people living with CIDP in Serbia

The Rulebook amending the List of Medicines prescribed and dispensed at the expense of mandatory health insurance funds has been published in the Official Gazette of the Republic of Serbia, introducing a new treatment option for:

• Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
• Primary Immunodeficiencies (PID)

The new option is HyQvia® (facilitated subcutaneous human immunoglobulin), which will be included on the reimbursement list of the Republic Health Insurance Fund of Serbia (RFZO) for these indications.

According to the published information, the therapy is expected to become available from 26 August 2026.

The introduction of an additional treatment option represents an important step toward expanding therapeutic choices and improving access to modern therapies for people living with CIDP in Serbia.

The decision on whether a specific treatment option is appropriate for an individual patient is made by a specialist physician, based on the patient’s medical condition and clinical criteria.

📄 Official Gazette of the Republic of Serbia:
https://pravno-informacioni-sistem.rs/slglrsNP-overview/all

This post is intended for informational purposes only. It does not constitute medical advice and does not represent endorsement or promotion of any manufacturer or therapy.